Institutionalizing M&A Excellence In Health Care

M&A deals, particularly smaller ones, are the lifeblood of the health care industry. Despite evident success in dealmaking, McKinsey says that pharma and medtech firms can benefit by bringing better consistency, transparency and accountability to their M&A programs.

The past few years have seen a boom in health care mega-mergers, with headline-worthy examples in both biopharma and medtech. In terms of total M&A deal value, 2014 was the most productive year in recent memory for medical devices, and 2015 was even more productive than 2014 for pharma. (See Exhibit 1.) (Also see Also see "Mega Medtech M&A Momentum In 2015" - In Vivo, 17 March, 2016..) This boom was fueled partly by the overcapacity that persists throughout the industry, particularly in support and commercial functions. That much is evident from the scale of the cost synergies announced in recent acquisitions. The largest acquisitions in the last year have declared significant cost synergies, even if that was not the main objective. In medtech, Medtronic PLC announced $850 million of cost savings when acquiring Covidien PLCin June 2014; and in Pharma, Pfizer Inc. announced a $2 billion cost synergy in the merger with Allergan PLC. [See Deal][See Deal]

However, these mega-mergers, while important in reducing overcapacity, have done little to change the rationale for most health care deals,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deal-Making

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By 

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

Deals Shaping The Industry, May 2025

 
• By 

An interactive look at pharma, medtech and diagnostics deals made during May 2025. Data courtesy of Biomedtracker.

Bringing Israeli Medical Device Candidates To The Right Partners In The US

 
• By 

Despite regional unrest, it is business as usual for medtech innovators and investors in Israel as evidenced by continued high-value M&A of locally developed technologies. Irit Yaniv, co-chair of the medtech session at the upcoming BioMed Israel 2025, explained the unique dynamics of Israeli medtech innovation.

Deals In Depth: April 2025

 
• By 

Four $1bn+ alliances were penned in April, and one exceeded $2bn.

More from In Vivo

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By 

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By 

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.